NCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
Clinical Trials
8 trialsNCT02236195 2017-09-01
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00324220 2015-07-01
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Mirati Therapeutics Inc.
Phase 1/2 Completed
NCT00359086 2015-07-01
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00372437 2015-07-01
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Mirati Therapeutics Inc.
Phase 1/2 Completed
NCT00431873 2015-07-01
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Phase 2 Completed
NCT00323934 2015-01-08
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Mirati Therapeutics Inc.
Phase 1 Completed
NCT00324194 2015-01-08
A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
Mirati Therapeutics Inc.
Phase 1 Completed